ZENPEP
LOE Approachingpancrelipase lipase, pancrelipase protease, pancrelipase amylase
BLAORALCAPSULE, DELAYED RELEASEPriority Review
Approved
Aug 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 12h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZENPEP is an oral delayed-release capsule containing a combination of pancreatic enzymes (lipase, protease, and amylase) used to treat pancreatic insufficiency by replacing missing digestive enzymes. It enables patients with conditions like cystic fibrosis and chronic pancreatitis to properly digest food and absorb nutrients.
$0.39MPart D
LOE ApproachingMature product approaching loss of exclusivity with minimal Part D volume signals a small, stable team focused on retention and niche positioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ZENPEP offers limited career expansion opportunity given the single linked job and minimal team scale. Career progression will depend on mastering mature-market strategies and competitive positioning in a price-sensitive generic landscape.
Alternance
Commercial
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.